Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and PK of M3814 in Combination With Etoposide and Cisplatin in Subjects With Treatment-naïve Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and PK of M3814 in Combination With Etoposide and Cisplatin in Subjects With Treatment-naïve Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and PK of M3814 in Combination With Etoposide and Cisplatin in Subjects With Treatment-naïve Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and PK of M3814 in Combination With Etoposide and Cisplatin in Subjects With Treatment-naïve Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and PK of M3814 in Combination With Etoposide and Cisplatin in Subjects With Treatment-naïve Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Status: Enrolling
Updated:  12/31/1969
Investigational Site Number 056010
mi
from
Aalst,
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and PK of M3814 in Combination With Etoposide and Cisplatin in Subjects With Treatment-naïve Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
Status: Enrolling
Updated: 12/31/1969
Investigational Site Number 056010
mi
from
Aalst,
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Duarte, CA
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orange, CA
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Miami, FL
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Miami, FL
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Augusta, GA
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Maywood, IL
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Maywood, IL
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Indianapolis, IN
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Scarborough, ME
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Baltimore, MD
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Detroit, MI
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Omaha, NE
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Las Vegas, NV
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Albany, NY
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Brooklyn, NY
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Winston-Salem, NC
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Kettering, OH
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chattanooga, TN
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Dallas, TX
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Phoenix, AZ
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Orange, CA
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Orange, CA
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
San Francisco, CA
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Tallahassee, FL
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Park Ridge, IL
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Hackensack, NJ
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Cincinnati, OH
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Hilliard, OH
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Hilliard, OH
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Galveston, TX
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Galveston, TX
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
Newark, NJ
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
Newark, NJ
Click here to add this to my saved trials
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated:  12/31/1969
Site
mi
from
La Rioja,
Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
Status: Enrolling
Updated: 12/31/1969
Site
mi
from
La Rioja,
Click here to add this to my saved trials
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Site US10044
mi
from
Tucson, AZ
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Site US10044
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Site US10016
mi
from
La Jolla, CA
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Site US10016
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Site US10001
mi
from
Los Angeles, CA
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Site US10001
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Site US10021
mi
from
Palo Alto, CA
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Site US10021
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
Site US10012
mi
from
Atlanta, GA
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
Site US10012
mi
from
Atlanta, GA
Click here to add this to my saved trials